{
  "abstract": "Background\n\nErectile dysfunction (ED) is a common disease condition with major psychosocial and clinical consequences. Over 50% of men aged 40 years and above are estimated to experience some level of ED. Phosphodiesterase type 5 inhibitors (PDE5Is) remain the mainstay of ED treatment. Sildenafil citrate orodispersible film (ODF) is a novel formulation designed to improve convenience and patient satisfaction. This study explored real-world perspectives and patient preferences regarding the use of sildenafil citrate ODF.Methods\n\nA cross-sectional, web-based survey was conducted in Italy (September-November 2024) in adult men using prescription ED medications. Data on demographics, lifestyle, clinical condition, treatment experiences, and patient perceptions about PDE5Is with a focus on sildenafil ODF were collected.Results\n\nThe survey included 276 men (mean age 47 years; 43.5% Viagra users, 25% Cialis users, 13.4% other branded ED medication users, and 18.1% generic ED medication users). Most were married (51%), employed (78%), and reported at least one comorbidity (75%), predominantly cardiovascular (53%). Film-coated tablets of PDE5 inhibitors were the most used formulation (72%), while 5% reported sildenafil ODF use.Awareness of sildenafil ODF was high, with valued attributes including water-free administration, portability, discretion, and faster perceived onset of action. Among overall ED medication users, 79% expressed willingness to adopt sildenafil ODF with 33% citing liking of the formulation and 28% citing perceived difference from already using medication. The main barrier to adoption was high cost compared to other ED medications, cited by 37% of the 21% participants who did not express willingness to adopt sildenafil ODF.Conclusion\n\nSildenafil ODF was widely perceived by patients as a discreet and practical alternative to conventional film-coated tablets, with high willingness for adoption. Aligning treatment choices with patient preferences may enhance adherence, satisfaction, and overall quality of life in ED management.",
  "abstract_shown": true,
  "affiliations": [
    "Section of Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.",
    "Viatris Inc., Milan, Italy.",
    "Viatris Italia S.R.L., Milan, Italy.",
    "Mylan Pharmaceuticals Pvt Ltd., a Viatris Company, Hyderabad, India.",
    "Deparment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Andrea Sansone",
      "orcid": "0000-0002-1210-2843"
    },
    {
      "affs": [
        1
      ],
      "name": "Franco M P Mondello Malvestiti"
    },
    {
      "affs": [
        2
      ],
      "name": "Raffaella Mantegazza"
    },
    {
      "affs": [
        3
      ],
      "name": "Shivani Ohri Vignesh"
    },
    {
      "affs": [
        4
      ],
      "name": "Emmanuele A Jannini",
      "orcid": "0000-0002-5874-039X"
    },
    {
      "affs": [
        1
      ],
      "name": "Carmen Ferrara"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1ajkwe61efcpw.bib",
  "cited_by": 0,
  "doi": "10.1093/sexmed/qfag095",
  "fulltext_url": "https://europepmc.org/articles/PMC13704790",
  "id": "1ajkwe61efcpw",
  "issns": [
    "2050-1161"
  ],
  "landing_url": "https://europepmc.org/article/MED/42936858",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2738|Sexual function and dysfunction studies"
    ]
  ],
  "openalex": "W7223679220",
  "pdf_url": "https://europepmc.org/articles/PMC13704790?pdf=render",
  "pmcid": "PMC13704790",
  "pmid": "42936858",
  "published": "2026-10-26",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/1ajkwe61efcpw.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:22:12Z",
      "native_id": "MED:42936858",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42936858"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2738|Sexual function and dysfunction studies",
      "subfield": "psychiatry"
    }
  ],
  "title": "Understanding patient perspectives and preferences on sildenafil orodispersible formulation: a survey-based evaluation of men using erectile dysfunction medications.",
  "title_text": "Understanding patient perspectives and preferences on sildenafil orodispersible formulation: a survey-based evaluation of men using erectile dysfunction medications.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:22:12Z",
  "url": "https://research.draconitic.com/paper/1ajkwe61efcpw",
  "venue": "Sexual medicine",
  "versions": []
}